Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06137001
Other study ID # C4591030
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 20, 2022
Est. completion date October 5, 2022

Study information

Verified date November 2023
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will assess the safety and immunogenicity of a fourth dose (booster) of BNT162b2 when coadministered with SIIV compared to separate administration of the vaccines when given 1 month apart (SIIV followed by BNT162b2), in participants who have received 3 prior doses of 30 µg BNT162b2, with the third dose being at least 90 days before Visit 1 (Day 1). - Healthy adults 18 through 64 years of age will be randomized 1:1 to either the co-administration group, or the separate administration group - The duration of the study for each participant will be approximately 2 months - There are 3 scheduled study visits each about 1 month apart - The study will be conducted in New Zealand and Australia.


Recruitment information / eligibility

Status Completed
Enrollment 1134
Est. completion date October 5, 2022
Est. primary completion date October 5, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion Criteria: 1. Participants 18 through 64 years of age, inclusive, at the time of consent. 2. Are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. 3. Adults determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study, including adults with preexisting stable disease, defined as disease not requiring significant change in therapy in the previous 6 weeks or hospitalization for worsening disease within 12 weeks before receipt of study intervention. 4. Have received 3 prior doses of 30 µg BNT162b2, with the third dose being at least 90 days before Visit 1 (Day 1). Documented confirmation of prior BNT162b2 receipt must be obtained prior to randomization. 5. Capable of giving personal signed informed consent, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol. Exclusion Criteria: 1. Other medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. 2. Allergy to egg proteins (egg or egg products) or chicken proteins. 3. History of Guillain-Barré syndrome. 4. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s). 5. A positive SARS-CoV-2 test result (either by NAAT or rapid antigen test) within 28 days of Visit 1 (Day 1). 6. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination. 7. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection. 8. Women who are pregnant or breastfeeding. 9. Vaccination with any influenza vaccine <6 months before study intervention administration, or planned receipt of any licensed or investigational nonstudy influenza vaccine during study participation. 10. Individuals who receive treatment with radiotherapy or immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids (if systemic corticosteroids are administered for =14 days at a dose of =20 mg/day of prednisone or equivalent), eg, for COPD, or planned receipt throughout the study. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted. 11. Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study. 12. Receipt of any passive antibody therapy specific to COVID-19 from 90 days before study intervention administration or planned receipt throughout the study. 13. Prior receipt of any COVID-19 vaccine other than BNT162b2 or receipt of more than 3 prior doses of BNT162b2. 14. Participation in other studies involving study intervention within 28 days prior to study entry and/or during study participation. 15. Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
BNT162b2
Intramuscular injection
Other:
Placebo
Saline intramuscular injection
Biological:
Seasonal Inactivated Influenza Vaccine
SIIV intramuscular injection

Locations

Country Name City State
Australia Paratus Clinical Research Brisbane Albion Queensland
Australia Northern Beaches Clinical Research Brookvale New South Wales
Australia Emeritus Research Camberwell Victoria
Australia Barwon Health Geelong Victoria
Australia Australian Clinical Research Network Sydney New South Wales
Australia AusTrials - Wellers Hill Wellers Hill Queensland
Australia Westmead Hospital Westmead New South Wales
New Zealand Aotearoa Clinical Trials Auckland
New Zealand Middlemore Clinical Trials Auckland
New Zealand Southern Clinical Trials Waitemata Ltd Auckland
New Zealand New Zealand Clinical Research (Christchurch) Christchurch Canterbury
New Zealand Pacific Clinical Research Network - Forte Christchurch Canterbury
New Zealand Lakeland Clinical Trials Wellington Ebdentown. Upper Hutt Wellington
New Zealand New Zealand Clinical Research (Auckland) Grafton Auckland
New Zealand Optimal Clinical Trials Grafton Auckland
New Zealand Lakeland Clinical Trials Waikato Hamilton Waikato
New Zealand P3 Research - Hawke's Bay Havelock North Hawke's BAY
New Zealand Southern Clinical Trials Tasman Nelson
New Zealand Southern Clinical Trials Totara New Lynn Auckland
New Zealand P3 Research - Palmerston North Palmerston North Manawatu-wanganui
New Zealand Lakeland Clinical Trials Culloden Papamoa Beach BAY OF Plenty
New Zealand P3 Research - Kapiti Paraparaumu Wellington
New Zealand Pacific Clinical Research Network - Rotorua Rotorua BAY OF Plenty
New Zealand P3 Research - Tauranga Tauranga BAY OF Plenty
New Zealand Capital, Coast and Hutt Valley District - Wellington Regional Hospital Wellington
New Zealand P3 Research - Wellington Wellington

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Countries where clinical trial is conducted

Australia,  New Zealand, 

Outcome

Type Measure Description Time frame Safety issue
Primary Local reactions (redness, swelling, and pain at the injection site) self-reported on e-diaries The percentage of participants reporting prompted local reactions within 7 days after each vaccination 7 days after each vaccination
Primary Systemic events (fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, and new or worsened joint pain) self-reported on e-diaries The percentage of participants reporting prompted systemic events within 7 days after each vaccination 7 days after each vaccination
Primary Adverse Events The percentage of participants reporting AEs within 1 month after each vaccination 1 month after each vaccination
Primary Serious Adverse Events The percentage of participants reporting SAEs from the first vaccination up to 1 month after the last vaccination 1 month after the last vaccination
Primary Full-length S-binding IgG levels Geometric mean ratio of full-length S-binding IgG levels 1 month after vaccination with BNT162b2 in the coadministration group to the IgG levels 1 month after vaccination with BNT162b2 in the separate administration group 1 month after vaccination with BNT162b2
Primary Strain-specific HAI titers ; H3N2-neutralizing antibody titers (if H3N2-HAI titers cannot be obtained) Geometric mean ratio of the strain-specific HAI (or H3N2-neutralizing antibody) titers 1 month after vaccination with SIIV in the coadministration group to the corresponding HAI (or H3N2-neutralizing antibody) titers in the separate administration group 1 month after vaccination with SIIV
Secondary Full-length S-binding IgG levels ; SARS-CoV-2 neutralizing titers (for a subset of approximately 200 participants) expressed as Geometric Mean Concentrations/Geometric Mean Titers Geometric Mean Concentrations/Geometric Mean Titers elicited by BNT162b2 when coadministered with SIIV or administered alone At baseline (before vaccination) and 1 month after vaccination with BNT162b2
Secondary Full-length S-binding IgG levels ; SARS-CoV-2 neutralizing titers (for a subset of approximately 200 participants) expressed as Geometric Mean Fold Rise Geometric Mean Fold Rise elicited by BNT162b2 when coadministered with SIIV or administered alone At baseline (before vaccination) and 1 month after vaccination with BNT162b2
Secondary Strain-specific HAI titers ; H3N2-neutralizing antibody titers (if H3N2-HAI titers cannot be obtained) expressed as Geometric Mean Titers Geometric Mean Titers elicited by SIIV when coadministered with BNT162b2 or administered alone At baseline (before vaccination) and 1 month after vaccination with SIIV
Secondary Strain-specific HAI titers ; H3N2-neutralizing antibody titers (if H3N2-HAI titers cannot be obtained) expressed as Geometric Mean Fold Rise Geometric Mean Fold Rise in strain-specific HAI titers elicited by SIIV when coadministered with BNT162b2 or administered alone At baseline (before vaccination) and 1 month after vaccination with SIIV
See also
  Status Clinical Trial Phase
Withdrawn NCT06065033 - Exercise Interventions in Post-acute Sequelae of Covid-19 N/A
Completed NCT06267534 - Mindfulness-based Mobile Applications Program N/A
Completed NCT05047601 - A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection Phase 2/Phase 3
Recruiting NCT04481633 - Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection N/A
Recruiting NCT05323760 - Functional Capacity in Patients Post Mild COVID-19 N/A
Completed NCT04612972 - Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru Phase 3
Completed NCT04537949 - A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults Phase 1/Phase 2
Recruiting NCT05494424 - Cognitive Rehabilitation in Post-COVID-19 Condition N/A
Active, not recruiting NCT06039449 - A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2 Phase 3
Enrolling by invitation NCT05589376 - You and Me Healthy
Completed NCT05158816 - Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
Recruiting NCT04341506 - Non-contact ECG Sensor System for COVID19
Completed NCT04512079 - FREEDOM COVID-19 Anticoagulation Strategy Phase 4
Completed NCT04384445 - Zofin (Organicell Flow) for Patients With COVID-19 Phase 1/Phase 2
Completed NCT05975060 - A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants. Phase 2/Phase 3
Active, not recruiting NCT05542862 - Booster Study of SpikoGen COVID-19 Vaccine Phase 3
Withdrawn NCT05621967 - Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation N/A
Terminated NCT05487040 - A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease Phase 1
Terminated NCT04498273 - COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Phase 3
Active, not recruiting NCT06033560 - The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure